Resources: Protease Inhibitors: Current Status

*** Protease Inhibitors: Current Status

"Protease Inhibitors: Overview and Analysis," by Dave Gilden,
with assistance from Ben Cheng, Rick Loftus, and others,
which appears in the March 1994 GMHC Treatment Issues, uses
both published articles and unpublished information from
within companies to provide an authoritative status report on
the protease inhibitors now in human trials. This class of
potential anti-HIV drugs is perhaps the most important group
of experimental treatments at the present time, although the
current candidates still face major problems -- including the
development of resistant strains of HIV, poor oral
absorption, and expense and difficulty of manufacture. The
article reviews the drugs of Hoffmann-La Roche, Merck, Abbot,
Searle (Monsanto), Vertex/Burroughs Wellcome, and Agouron; it
also names a number of other companies which are developing
protease inhibitors that are not yet in human trials.

To obtain a free copy of the March 1994 issue, write to:
GMHC, Medical Information, 129 West 20th St., New York, NY
10011.

[GMHC Treatment Issues is published 12 times a year; annual
subscriptions are available for a suggested donation of $30
individual, $50 physicians and institutions, and $60 foreign;
persons with AIDS or HIV can contribute on a sliding scale or
obtain a free subscription. You can ask to have your
subscription start at the beginning of 1994, and include the
special winter 1993/1994 issue on alternative treatments.]

Note: Dave Gilden, formerly a San Francisco-based freelance
writer who often appeared in AIDS TREATMENT NEWS, recently
moved to New York to become editor of GMHC Treatment Issues.